COLUMBIA, Md., July 30 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a late stage biotechnology drug development company that is leveraging its heat sensitive liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it would hold a conference call to discuss second quarter 2010 results at 11:00 a.m. ET on Tuesday, August 3, 2010.  To participate in the call, interested parties may dial 1-888-806-6230 (Toll-free) or 1-913-227-1353 (International/Toll) and use Conference ID: 1474955 to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.

The call will be archived for replay on Tuesday, August 3, 2010 at 2:00 p.m. ET and will remain available until Tuesday, August 10, 2010.  The replay can be accessed at 1-877-870-5176 (Toll-free) or 1-858-384-5517 (International/Toll) using Conference ID: 1474955. An audio replay of the call will also be available on the Company's website, http://www.celsion.com, for 30 days after 3:00 P.M. ET on Tuesday, August 3, 2010.

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox® to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website: http://www.celsion.com

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

ThermoDox® is a registered trademark of Celsion Corporation

SOURCE Celsion Corporation

Back to top

RELATED LINKS
http://www.celsion.com